p-ANCA target antigens in ulcerative colitis

Zeitschrift fur Gastroenterologie

Volumn 36, Issue 8, 1998, Pages 625-633

  Folwaczny, C ^a   Jochum, M ^b   Noehl, N ^a   Schnettler, D ^a   Loeschke, K ^a   Fricke, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bactericidal permeability increasing protein (BPI); Cathepsin G; Elastase; Lactoferrin; Myeloperoxidase; Perinuclear antineutrophil cytoplasmatic autoantibodies (p ANCA); Ulcerative colitis

Indexed keywords

AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHEPSIN G; ELASTASE; LACTOFERRIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; COLITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIGENS; COLITIS, ULCERATIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED;

EID: 0031719108     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9
2. Goldschmeding R, Van der Schott CE, ten Bokkel Huinink D et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorosphosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84: 1577-87
3. Goldschmeding R, Cohen Tervaert JW, Gans RO et al. Different immunological specifities and disease associations of c-ANCA. Neth J Med 1990; 36: 114-6
4. Goldschmeding R, Dolman KM, Van den Ende ME et al. The relation of 29 kD c-ANCA antigen to proteinase 3. APMIS (suppl.) 1990; 19: 26-7
5. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-7
6. Cohen Tervaert JW, Goldschmeding R, Elema JD et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990; 33: 1264-72
7. Cohen Tervaert JW, Goldschmeding R, Elema JD et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990; 37: 799-806
8. Cohen Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11
9. Kallenberg CG, Goldschmeding R, Cohen Tervaert JW. Von dem Borne AE. Autoantibodies to myeloid lysosomal enzymes: New clues to vasculitis and glomerulonephritis. A hypothesis based on humoral immune mechanisms. Neth J Med 1990; 36: 163-8
10. Saxon A, Shanahan F, Landers C, Ganz T, Targan S, A distinct subset of antineutrophil cytoplasmic anti bodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202-10
11. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparision with other colitides/diarrheal illnesses. Gastroenterology 1991; 100: 1590-6
12. Duerr RH, Targan SR, Landers CJ et al. Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385-91
13. Cambridge C, Rampton D, Stevens DR et al. Antineutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 1992; 33: 668-74
14. Shanahan F, Duerr RH, Rotter JI et al. Neutrophil autoantibodies in ulcerative colitis: Familial ageregation and genetic heterogeneity. Gastroenterology 1992; 103: 456-61
15. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107: 532-6
16. Reumaux D, Delecourt L, Colombel JF et al. Antineutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis (letter; comment). Gastroenterology 1992; 103: 1706
17. Papo M, Quer JC, Pastor MR et al. Antineutrophil cytoplasmatic antibodies in relatives of patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91: 1512-5
18. Broekroelofs J, Mulder AH, Nelis GF et al. Antineutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity. Dig Dis Sci 1994; 39: 545-9
19. Colombel JF, Reumaux D, Duthilleul P et al. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol Clin Biol 1992; 16: 656-60
20. Halbwachs-Mecarelli L, Nusbaum P, Noel LH et al. Antineutrophil eytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992; 90: 79-84
21. Mulder AG, Broekroelofs J, Horst G et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: Characterization and clinical correlates. Clin Exp Immunol 1994; 95: 490-7
22. Skogh T, Peen E. Lactoferrin, anti-lactoferrin antibodies and inflammatory disease. Adv Exp Med Biol 1993; 336: 533-8
23. Schumacher G, Kollberg B, Sandstedt B, Ljungh A, Nassberger L. Circulating granulocyte antibodies in first attacks of colitis. Scand J Gastroenterol 1995; 30: 157-63
24. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978; 253: 2664-72
25. Walsmley RS, Zhao MH, Hamilton MI et al. Antineutrophil cytoplasm autoantibodies against bactericidial/permeability increasing protein in inflammatory bowel disease. Gut 1997; 40: 105-9
26. Stoffel MP, Csernok E, Gross WL. Target antigen for anti-neutrophil cytoplasmatic antibodies in inflammatory bowel disease. Scand J Gastroenterol 1996; 31: 943-4
27. Marra MN, Wilde CG, Collins MS et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532-7
28. Monajemi H, Meenan J, Lamping R et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability increasing protein. Gastroenterology 1996; 110: 733-9
29. Animons WS, Kohn FR, Kung AHC. Protective effects of a N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: Role of bactericidal properties. J Infect Dis 1994; 170: 1473-82
30. Stoffel MP, Csernok E, Herzberg C et al. Anti-neutrophil cytoplasmatic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): A new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996; 104: 54-9
31. Romas E, Paspaliaris B, d'Apice AJ, Elliott PR. Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease. Aust N Z J Med 1992; 22: 652-9
32. Yang H, Rotter JI, Toyoda H et al. Ulcerative colitis: A genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92: 1080-4
33. Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995; 108: 428-33
34. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H. Pancreatic- and antineutrophil autoantibodies in first-degree relatives of patients with inflammatory bowel disease (IBD). Gastroenterology 1996; 110: A908
35. Ammons WS, Kung AHC. Recombinant amino terminal fragment of bactericidal/permeability increasing protein prevents hemodynamic response to endotoxin. Circ Shock 1993; 41: 176-84
36. Gazzano-Santoro H, Parent JB, Grinna L et al. High affinity binding of the bactericidal/permeability increasing protein and a recombinant amino terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992; 60: 4754-61
37. Falk RJ, Becker M, Terell R, Jennette JC. Antigen specificity of pANCA and of cANCA. Am J Kidney Dis 1991; 19: A197
38. Zhao Mil, Jones SJ, Lockwood CM. Bactericidal/permeability increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmatic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995; 99: 49-56
39. Yang JJ, Becker M, Tuttle R et al. Specificity of cytoplasmatic-pattern anti-neutrophil cytoplasmatic autoantibodies (cANCA) for bactericidal permeability increasing protein. Clin Exp Immunol 1995; 101 (suppl.) 1: 50
40. Peen E, Almer S, Bodemar G et al. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 1993; 34: 56-62
41. Mayet WJ, Hermann E, Finsterwalder J et al. Antibodies to Cathepsin G in Crohn's disease. Eur J Clin Invest 1989; 22: 427-33
42. Patel RT, Stokes R, Birch D, Ibbotson J, Keighley MR. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br J Surg 1994; 81: 724-6
43. Kim WH, Choi PM, Landers CJ, Targan SR. Role on antineutrophil cytoplasmic antibodies in an ethnically distinct population: Korean patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 1953-8
44. Folwaczny C, Noehl N, Endres SP et al. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 523-9